Prader-Willi Syndrome Stocks
Clinical-stage biopharmaceutical firms in this sector focus on addressing the complex neuroendocrine and behavioral symptoms of Prader-Willi Syndrome, specifically targeting hyperphagia and metabolic dysfunction. Revenue potential hinges on securing orphan drug designations and navigating rigorous FDA pathways for rare genetic disorders with zero currently approved curative treatments.
As of Oct 23, 2026, Prader-Willi Syndrome has 4 US-listed companies worth $3.1B combined. The median member moved -1.2% over the past week; RLMD led at +5.5% and AARD trailed at -63.2%.
Companies in Prader-Willi Syndrome
- HRMY – Harmony Biosciences Holdings, $2.1B
- DRUG – Bright Minds Biosciences Inc, $506M
- RLMD – Relmada Therapeutics Inc, $347M
- AARD – Aardvark Therapeutics, Inc. Common Stock, $104M